AAP
BBIO icon

Arax Advisory Partners’s BridgeBio Pharma BBIO Stock Holding History

Arax Advisory Partners’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$77.2K Buy
1,036
+515
+99% +$36.1K ﹤0.01% 2926
2026
Q1 		$33.8K Buy
521
+425
+443% +$30.8K ﹤0.01% 1843
2025
Q4 		$7.34K Sell
96
-711
-88% -$46.7K ﹤0.01% 2645
2025
Q3 		$41.9K Buy
807
+437
+118% +$21.3K ﹤0.01% 1909
2025
Q2 		$16K Buy
+370
New +$13.5K ﹤0.01% 1750
2024
Q3 		– Sell
-51
Closed -$1.29K – 2625
2024
Q2 		$1.29K Buy
+51
New +$1.39K ﹤0.01% 2101

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Arax Advisory Partners's BBIO Position: Q2 2026 in Review

Arax Advisory Partners increased its BridgeBio Pharma (BBIO) stake by 99% in Q2 2026, buying an estimated $36.1K and bringing the position to 1,036 shares worth $77.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2926.

Arax Advisory Partners first reported a position in BBIO in Q2 2024 and has held it in 6 quarters since. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Arax Advisory Partners held 1,036 shares of BridgeBio Pharma worth $77.2K as of Q2 2026.
  • Arax Advisory Partners bought 515 BridgeBio Pharma shares in Q2 2026, an estimated $36.1K.
  • BridgeBio Pharma made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #2926 holding.
  • Arax Advisory Partners first reported a position in BridgeBio Pharma in Q2 2024 and has held it in 6 quarters since.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.